Last reviewed · How we verify
NDV-3 vaccine with alum IM — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
NDV-3 vaccine with alum IM (NDV-3 vaccine with alum IM) — NovaDigm Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NDV-3 vaccine with alum IM TARGET | NDV-3 vaccine with alum IM | NovaDigm Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NDV-3 vaccine with alum IM CI watch — RSS
- NDV-3 vaccine with alum IM CI watch — Atom
- NDV-3 vaccine with alum IM CI watch — JSON
- NDV-3 vaccine with alum IM alone — RSS
Cite this brief
Drug Landscape (2026). NDV-3 vaccine with alum IM — Competitive Intelligence Brief. https://druglandscape.com/ci/ndv-3-vaccine-with-alum-im. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab